Health Economics›CNS lymphoma›Relapsed or refractory subsequent lines of therapy

Relapsed or refractory subsequent lines of therapy

CNS lymphoma · 4 regimens

Cost estimates only — modelled on a typical patient (BSA 1.7 m², 70 kg, CrCl 90 mL/min) using the cheapest available formulary presentation. Excludes vial wastage, facility fees, supportive care, and infusion consumables. Not for billing, formulary decisions, or clinical use.

Filters

Y-axis

Cost vs Efficacy · 4 points

Fully pricedPartial pricing

Regimen	Biomarker	Cost/cycle ↓	Cycle	PFS ↕	OS ↕	Est. cycles	Course cost ↕	Evidence
Topotecan monotherapy Variant #01	—	R 11 563	21d	~4.4 mo	~8.5 mo	~7	~R 80 942 PFS proxy · indirect	21
Temozolomide monotherapy Variant #13	—	R 8 153	28d	~4.0 mo	~16.3 mo	~5	~R 40 764 PFS proxy · indirect	10
Rituximab monotherapy N/A - secondary systemic drug	—	R 52	180d	~5.2 mo	—	~1	~R 52 PFS proxy · indirect	3
Temsirolimus monotherapy N/A - secondary systemic drug	—	R 0	28d	~4.8 mo	~23.5 mo	~6	~R 1 PFS proxy · indirect	2

4 of 4 regimens shown